Expressing Conviction in Pacira’s IP and Belief in Undervalued Shares
DOMA Perpetual Capital Management Urges Pacira to Commence Stock Tender Offer
MIAMI, Dec. 11, 2024 /PRNewswire/ — DOMA Perpetual Capital Management LLC (DOMA), which owns approximately 4.14% of the outstanding shares of Pacira BioSciences, Inc. (NASDAQ: PCRX), announced its intention to nominate four independent director candidates at the Company’s 2025 annual meeting of stockholders. DOMA has also hired Olshan Frome Wolosky LLP as counsel to represent it in dealings with the Company. DOMA believes in the value of Pacira’s intellectual property and views the stock as significantly undervalued, urging the Company to initiate a stock tender offer for 10 million shares using its cash on hand, followed by a $150 million buyback program.
Expressing conviction in Pacira’s intellectual property and overall company performance, DOMA Perpetual Capital Management is taking proactive steps to advocate for shareholder interests. With a focus on maximizing shareholder value, DOMA sees potential for growth and believes that the Company’s stock is currently trading below its intrinsic value. By urging Pacira to take immediate action through a stock tender offer and share buyback program, DOMA aims to unlock the true potential of the Company and enhance returns for all shareholders.
With its reputation for being professionally managed and profit-focused, DOMA’s strategic approach sends a clear message to Pacira and the market about the untapped value within the Company. By nominating independent director candidates and engaging legal counsel, DOMA is positioning itself as a proactive force for change within Pacira, advocating for transparency, accountability, and shareholder-friendly initiatives. Through these actions, DOMA is expressing confidence in Pacira’s intellectual property and calling for the Company to capitalize on its strong financial position to drive further growth and value creation.
As shareholders evaluate the implications of DOMA’s stance on Pacira, the market may see increased volatility and renewed interest in the Company’s stock. Potential changes in board composition and strategic direction could impact investor sentiment and shape future decisions around investments in Pacira. Additionally, Pacira’s response to DOMA’s recommendations will signal its commitment to shareholder value and may influence perceptions of the Company’s governance and long-term growth prospects.
Impact on Me
As a shareholder of Pacira BioSciences, the actions taken by DOMA Perpetual Capital Management could directly affect the value of my investment. The proposed nominations of independent director candidates and the call for a stock tender offer and buyback program may lead to changes in the Company’s strategic direction and operational focus, impacting the stock price and overall shareholder returns.
Impact on the World
DOMA Perpetual Capital Management’s advocacy for shareholder value and corporate governance at Pacira BioSciences sets a precedent for investor activism and engagement in the biopharmaceutical sector. By highlighting the importance of intellectual property and financial performance, DOMA’s actions may influence how companies in the industry are managed and governed, ultimately shaping the future of innovation and value creation in healthcare.
Conclusion
In conclusion, DOMA Perpetual Capital Management’s conviction in Pacira’s intellectual property and belief in undervalued shares reflect a commitment to maximizing shareholder value and driving positive change within the Company. By urging Pacira to take immediate steps to unlock growth potential and enhance returns, DOMA is advocating for transparency, accountability, and long-term value creation. The impact of DOMA’s actions on Pacira and the wider market underscores the significance of shareholder activism in shaping corporate governance and driving sustainable growth in the biopharmaceutical industry.
